2018-2019 AdooQ Catalog Book Available Click here to download

SGLT



10 Item(s)

per page

Set Descending Direction
Catalog No. Product Name Application Product Information
A10285 SALE

Dapagliflozin (BMS512148)

SGLT2 inhibitor
Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney.
A13476

Luseogliflozin

SGLT2 Inhibitor
Luseogliflozin is an orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor developed by Taisho Pharmaceutical for the treatment of patients with type 2 diabetes mellitus (T2DM).
A13556 SALE

Ipragliflozin

SGLT2 inhibitor
Ipragliflozin is a highly potent and selective SGLT2 inhibitor with IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.
A13971

Remogliflozin

SGLT2 inhibitor
Remogliflozin inhibits the sodium-glucose transport (SGLT2) proteins, which are responsible for glucose reabsorption in the kidney.
A12690

Tofogliflozin

SGLT2 inhibitor
Tofogliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney.
A12680 SALE

LX-4211

SGLT Inhibitor‎
LX4211 is a Dual SGLT1/SGLT2 Inhibitor
A12440 SALE

Empagliflozin

-
Empagliflozin is a potent, selective sodium glucose co-transporter-2 inhibitor that is in development for the treatment of type 2 diabetes.
A10155

EGT1442

SGLT2 inhibitor
EGT1442 is a potent and selective SGLT2 inhibitor.
A11100 SALE

Canagliflozin

SGLT2 Inhibitor
Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2).
A15463 SALE

T-1095

Na+-glucose transporter inhibitor
T-1095 is a potent and selective inhibitor of Na+-glucose cotransporters (SGLTs).

10 Item(s)

per page

Set Descending Direction